FDA lifts clinical hold on Gilead’s investigational HIV treatment
The agency has removed the hold placed on the pharmaceutical company’s IND for injectable lenacapavir, which is intended for HIV treatment and prevention.
Headlines
Global Industry News
-
AbbVie and Cugene ink autoimmune therapy partnership
from BioPharma-Reporter.com
-
Korea’s Lotte plans to scale its biologics CDMO business in North America as it buys BMS site
from BioPharma-Reporter.com
-
RQ Bio launches to develop therapies based on broad-spectrum mAbs
from BioPharma-Reporter.com
-
BeiGene opens regional office in Basel to strengthen European presence
from BioPharma-Reporter.com
Hot Topics
-
Novartis looks to work more strategically as CDMO
Globalization
-
Elligo, Whyze Health partner to expand reach to European patients
Globalization
-
Collaboration, communication can benefit patient advocacy groups: IQVIA
Patient centricity
-
Reify Health funnels $220m into trial diversity effort
Patient centricity
